Trials / Completed
CompletedNCT00280956
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,000 (estimated)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | natalizumab |
Timeline
- Start date
- 2002-07-01
- Primary completion
- 2004-09-01
- Completion
- 2004-09-01
- First posted
- 2006-01-24
- Last updated
- 2016-06-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00280956. Inclusion in this directory is not an endorsement.